Literature DB >> 18278785

Telomere biology in giant cell tumour of bone.

R G Forsyth1, G De Boeck, S Bekaert, T De Meyer, A H M Taminiau, D Uyttendaele, H Roels, M M Praet, P C W Hogendoorn.   

Abstract

Giant cell tumour of bone (GCTB) is a benign bone tumour known for the unpredictable clinical behaviour of recurrences and, in rare instances, distant metastases. It consists of uniformly distributed osteoclastic giant cells in a background of mononuclear rounded and spindle-shaped cells. Cytogenetically, telomeric associations are the most common chromosomal aberrations, which, however, are normally almost exclusively found in high-grade malignancies. GCTB has often been regarded as a polyclonal tumour, but more recently a recurrent specific aberration was reported, which suggests a possible role for disturbed telomere maintenance. Here we further investigate telomere maintenance in GCTB using 19 samples from 19 patients. A combination of immunofluorescence and FISH was performed, applying antibodies directed against promyelocytic leukaemia body-related antigen and hTERT and using telomere peptide nucleic acid probes. The TRAP assay and telomere restriction fragment length analysis were performed for functional detection of telomerase activity and alternative telomere lengthening. Both osteoclastic giant cells and mononuclear cells showed positivity for hTERT and promyelocytic leukaemia body-related antigen. In most mononuclear cells, co-expression was present. The TRAP assay demonstrated heterogeneous telomerase activity, while telomere restriction fragment length analysis showed non-heterogeneous telomere lengths, indicating the absence of alternative telomere lengthening. Confocal microscopy showed stereometric co-localization of nucleolin with promyelocytic leukaemia body-related antigen in association with telomeres in the spindle-shaped cells. hTERT was more diffusely distributed throughout the nucleus. Our results show that GCTB demonstrates remarkable telomere maintenance of activated telomerase and inactivated alternative telomere lengthening in the presence of normal mean telomere restriction fragment lengths. These findings strongly suggest that these aggregates, while activating telomerase, are part of a structural telomere protective-capping mechanism rather than of a telomere-lengthening mechanism. Telomere maintenance could be considered an important key factor in the pathogenesis of GCTB. Copyright (c) 2008 Pathological Society of Great Britain and Ireland

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278785     DOI: 10.1002/path.2301

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone.

Authors:  M Alberghini; K Kliskey; T Krenacs; P Picci; L Kindblom; R Forsyth; N A Athanasou
Journal:  Virchows Arch       Date:  2009-12-15       Impact factor: 4.064

Review 2.  Prognosis of local recurrence in giant cell tumour of bone: what can we do?

Authors:  Yifeng He; Ji Zhang; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

Review 3.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

4.  Histological and clinical characteristics of malignant giant cell tumor of bone.

Authors:  Lihua Gong; Weifeng Liu; Xiaoqi Sun; Constantin Sajdik; Xinxia Tian; Xiaohui Niu; Xiaoyuan Huang
Journal:  Virchows Arch       Date:  2012-02-17       Impact factor: 4.064

5.  Clinical Scenario and Imaging with Illustrations of Giant Cell Tumor of Bone: A Retrospective Analysis.

Authors:  Nadeem Ali; Azad Ahmad Shah; Ibreez Rakshan
Journal:  Arch Bone Jt Surg       Date:  2022-01

6.  A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases.

Authors:  Ira J Miller; Alan Blank; Suellen M Yin; Allison McNickle; Robert Gray; Steven Gitelis
Journal:  Diagn Pathol       Date:  2010-09-22       Impact factor: 2.644

7.  A short-term in vivo model for giant cell tumor of bone.

Authors:  Maurice Balke; Anna Neumann; Károly Szuhai; Konstantin Agelopoulos; Christian August; Georg Gosheger; Pancras Cw Hogendoorn; Nick Athanasou; Horst Buerger; Martin Hagedorn
Journal:  BMC Cancer       Date:  2011-06-13       Impact factor: 4.430

8.  Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.

Authors:  Peter Balla; Mate Elod Maros; Gabor Barna; Imre Antal; Gergo Papp; Zoltan Sapi; Nicholas Anthony Athanasou; Maria Serena Benassi; Pierro Picci; Tibor Krenacs
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

9.  p63 regulates cell proliferation and cell cycle progression‑associated genes in stromal cells of giant cell tumor of the bone.

Authors:  Carol Po Ying Lau; Patrick Kwok Shing Ng; Man Shan Li; Stephen Kwok Wing Tsui; Lin Huang; Shekhar Madhukar Kumta
Journal:  Int J Oncol       Date:  2012-12-03       Impact factor: 5.650

10.  Giant cell tumor of bone revisited.

Authors:  Andreas F Mavrogenis; Vasileios G Igoumenou; Panayiotis D Megaloikonomos; Georgios N Panagopoulos; Panayiotis J Papagelopoulos; Panayotis N Soucacos
Journal:  SICOT J       Date:  2017-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.